Semaglutide
Brand names: Ozempic, Rybelsus · Active ingredient: Semaglutide
In short: RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2
What is Semaglutide used for?
RYBELSUS and OZEMPIC tablets are indicated:
•
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
•
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
⚠ Boxed warning (FDA's strongest warning)
•
In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined .
•
RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS or OZEMPIC tablets .
Semaglutide dosage
•
RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.
•
Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water
.
•
Do not take more than one tablet per day.
•
Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.
•
After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications
.
•
If a dose is missed, skip the missed dose and take the next dose the following day.
RYBELSUS: Recommended Dosage
Follow the RYBELSUS starting, escalation, and maintenance dosage described below to reduce the risk of gastrointestinal (GI) adverse reactions
:
•
Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).
•
Escalation and Maintenance Dosage (Days 31 and beyond):
o
Days 31 to 60: Increase the dosage to 7 mg orally once daily.
o
On Day 61 or thereafter, if:
▪
No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily.
▪
Additional glycemic control is needed, increase the dosage to 14 mg orally once daily.
OZEMPIC Tablets: Recommended Dosage
Follow the OZEMPIC tablets starting, escalation, and maintenance dosage described below to reduce the risk of GI adverse reactions
:
•
Starting Dosage (Initiation Phase) (Days 1 through 30): The recommended starting dosage is 1.5 mg orally once daily (this dosage is not effective for glycemic control).
•
Escalation and Maintenance Dosage (Days 31 and beyond):
o
Days 31 to 60: Increase the dosage to 4 mg orally once daily.
o
On Day 61 or thereafter, if:
▪
No additional glycemic control is needed, maintain the dosage at 4 mg orally once daily.
▪
Additional glycemic control is needed, increase the dosage to 9 mg orally once daily.
•
Do not switch between RYBELSUS and OZEMPIC tablets during the initiation phase (Days 1 to 30)
.
•
After 30 days of RYBELSUS or OZEMPIC tablet treatment (after the initiation phase)
, patients may switch between RYBELSUS and OZEMPIC tablet products .
•
When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product.
Table 1. Switching Between Escalation or Maintenance Dosage of RYBELSUS and OZEMPIC Tablets
RYBELSUS | OZEMPIC Tablets
7 mg orally once daily | 4 mg orally once daily
14 mg orally once daily | 9 mg orally once daily
Switching from OZEMPIC Injection to RYBELSUS Tablets
•
Patients taking the 0.5 mg dose of OZEMPIC injection may switch to RYBELSUS tablets. …
How to take Semaglutide — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Risk of Thyroid C-cell Tumors
Inform patients that semaglutide causes thyroid C-cell tumors in rodents and that the human relevance of this finding has not been determined. Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia or dyspnea) to their physician .
Acute Pancreatitis
Inform patients of the potential risk for acute pancreatitis and its symptoms: severe abdominal pain that may radiate to the back, and which may or may not be accompanied by nausea or vomiting. Instruct patients to discontinue RYBELSUS or OZEMPIC tablets promptly and contact their physician if pancreatitis is suspected .
Diabetic Retinopathy Complications
Inform patients to contact their physician if changes in vision are experienced during treatment with RYBELSUS or OZEMPIC tablets .
Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
Inform patients that the risk of hypoglycemia is increased when RYBELSUS or OZEMPIC tablets are used with an insulin secretagogue (such as a sulfonylurea) or insulin. Educate patients on the signs and symptoms of hypoglycemia . …
Warnings & precautions
Do not take this medicine if: RYBELSUS and OZEMPIC tablets are contraindicated in patients with:
•A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) .
•A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets .
In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures . It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.
RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS or OZEMPIC tablets. Such monitoring may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease. …
Semaglutide side effects
The following serious adverse reactions are described below or elsewhere in the prescribing information:
•Risk of Thyroid C-cell Tumors
•Acute Pancreatitis
•Diabetic Retinopathy Complications
•Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
•Acute Kidney Injury Due to Volume Depletion
•Severe Gastrointestinal Adverse Reactions
•Hypersensitivity Reactions
•Acute Gallbladder Disease
•Pulmonary Aspiration During General Anesthesia or Deep Sedation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of OZEMPIC tablets (1.5 mg, 4 mg and 9 mg strengths) and RYBELSUS (3 mg, 7, mg and 14 mg strengths) has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus . Below is a display of the safety results of the adequate and well-controlled studies of RYBELSUS (referred to below as semaglutide tablets) in adult patients with type 2 diabetes mellitus.
Pool of Placebo-Controlled Trials
The data in Table 2 are derived from 2 placebo-controlled trials in adult patients with type 2 diabetes mellitus . …
Drug interactions
Semaglutide stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving RYBELSUS or OZEMPIC tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
When initiating RYBELSUS or OZEMPIC tablets, consider reducing the dosage of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia .
Semaglutide cause a delay of gastric emptying and thereby has the potential to impact the absorption of other oral drugs. Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study .
When using RYBELSUS or OZEMPIC tablets concomitantly with other oral drugs that have a narrow therapeutic index or that require clinical monitoring, consider increased clinical or laboratory monitoring .
About this medicine
RYBELSUS and OZEMPIC tablets, for oral use, contain semaglutide, a GLP-1 receptor agonist. The peptide backbone is produced by yeast fermentation. The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. Furthermore, semaglutide is modified in position 8 to provide stabilization against degradation by the enzyme dipeptidyl-peptidase 4 (DPP-4). A minor modification was made in position 34 to ensure the attachment of only one fatty di-acid. The molecular formula is C187H291N45O59 and the molecular weight is 4113.58 g/mol.
Structural formula:
Semaglutide is a white to almost white hygroscopic powder.
RYBELSUS tablets contain 3 mg, 7 mg or 14 mg of semaglutide and the following inactive ingredients: magnesium stearate, microcrystalline cellulose, povidone and salcaprozate sodium (SNAC).
OZEMPIC tablets contain 1.5 mg, 4 mg or 9 mg of semaglutide and the following inactive ingredients: magnesium stearate and SNAC. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 27f15fac-7d98-4114-a2ec-92494a91da98. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Insulin Glargine Empagliflozin Glipizide Insulin Lispro Dulaglutide